| Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile C Federico, J Sun, B Muz, K Alhallak, PF Cosper, N Muhammad, A Jeske, ... International Journal of Radiation Oncology* Biology* Physics 109 (5), 1483-1494, 2021 | 51 | 2021 |
| Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges K Alhallak, J Sun, A Jeske, C Park, J Yavner, H Bash, B Lubben, ... Cancers 13 (12), 2853, 2021 | 12 | 2021 |
| Nanoparticle T cell engagers for the treatment of acute myeloid leukemia K Alhallak, J Sun, B Muz, A Jeske, J Yavner, H Bash, C Park, B Lubben, ... Oncotarget 12, 2021 | 8 | 2021 |
| 3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance K Alhallak, P de la Puente, A Jeske, J Sun, B Muz, MP Rettig, I Sahin, ... Leukemia & Lymphoma, 1-9, 2021 | 7 | 2021 |
| Vector Strategies to Actualize B Cell–Based Gene Therapies AM Jeske, P Boucher, DT Curiel, JE Voss The Journal of Immunology 207 (3), 755-764, 2021 | 6 | 2021 |
| Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma B Muz, K Wasden, K Alhallak, A Jeske, F Azab, J Sun, J King, DR Kohnen, ... BLOOD 136, 2020 | 4 | 2020 |
| Ex-Vivo 3D-Cultures of Patient-Derived Primary MM cells Retrospectively Predicts Treatment Clinical Outcomes in MM Patients K Azab, F Azab, A Jeske, R Vij Clinical Lymphoma, Myeloma and Leukemia 19 (10), e241-e242, 2019 | 2 | 2019 |
| 3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Predicts Clinical Efficacy of Drugs Better Than Regular Culture Systems in Multiple Myeloma A Jeske, AK Azab Blood 130 (Supplement 1), 3147-3147, 2017 | 1 | 2017 |
| 3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Retrospectively Predicts Treatment Clinical Outcomes of Multiple Myeloma Patients A Jeske, F Azab, P De La Puente, B Muz, J King, DR Kohnen, R Vij, ... Blood 132 (Supplement 1), 1987-1987, 2018 | | 2018 |
